{COVID-19} Pandemic Vomit VI

[Vaspinne]

Weren't double pfizer or double moderna both touted as having a 95% efficacy or something like that?

[Rhyis.]

i'm sure it has something to do with the dosage amount and we add a diluting agent (salt) to pfizer but not moderna. i dunno if the states does that

[Mertron]

we get 5g in ours

[Yabby]

[Kaslo]

we get 5g in ours

And it caused people to tear down those towers because of it.

[kuronosan]

i'm sure it has something to do with the dosage amount and we add a diluting agent (salt) to pfizer but not moderna. i dunno if the states does that

Not really, the concentration in a vaccine isn't dependent on the volume of vaccine. It's titrated to the volume of the diluent, so there isn't a difference in dosing from 3ml to 5ml if the vaccine concentration is the same.

Either way, Pfizer and Moderna are both mRNA vaccines so they should work in tandem. It'd be different if you get something like Pfizer/Moderna and then Novavax, AZ, or J&J.

[Tyrath]

Well thats why I initially asked because Vaspinne said people with 1st dose of AZ were getting Moderna 2nd dose.

[kuronosan]

Well thats why I initially asked because Vaspinne said people with 1st dose of AZ were getting Moderna 2nd dose.

As I said before, that would still potentiate the first dose. It likely wouldn't be as robust a response as it would be with like vaccines. It would be two different responses as the AZ vaccine is an attenuated adenovirus vaccine. Moderna would basically boost the AZ response in a different way. It's like treating blood pressure with a beta blocker and a renal adjunct like Lisinopril. Two different mechanisms with some synergistic effect.

[Rhyis.]

from that link i used before they talk about mixing az with pfizer but there's absolutely nothing about moderna in terms of trial studies.

Spoiler: show

Option 2: Receive an mRNA (Pfizer-BioNTech or Moderna) vaccine for
a second dose
• In line with basic principles of vaccinology, it is expected that combining different
COVID-19 vaccines that induce an immune response against the SARS-CoV-2
spike protein will lead to a robust immune response.
• There is evidence that providing an mRNA vaccine after AstraZeneca COVID-19
vaccine will boost the immune response
o A recent study from Spain (Borobia et al., 2021/CombiVacS) demonstrated
that a heterologous vaccine schedule of an AstraZeneca COVID-19 vaccine
followed by a dose of the Pfizer BioNTech COVID-19 vaccine produces a
strong immune response, as measured by antibodies following the second
dose, when compared to study participants with only a single dose of the
AstraZeneca COVID-19 vaccine.
o In a recent observational study (Barros-Martins et al, 2021), using a ~10.5
week interval between doses, a Pfizer-BioNTech boost following
AstraZeneca COVID-19 vaccine was found to induce a heightened humoral
and T cell immune response compared to the homologous AstraZeneca
COVID-19 vaccine schedule, including an increased neutralizing antibody
response against the Alpha, Beta and Gamma VOCs. The significance of
these findings with regard to effectiveness and duration of protection is
unknown due to a lack of a defined immunological correlate of protection for
SARS-CoV-2 infection.
o Studies involving heterologous schedules with vaccines using different
platforms are ongoing, including the MOSAIC CIRN Canadian study. The
CoM-Cov randomised clinical trial from the United Kingdom (UK), compared
four combinations of the AstraZeneca and Pfizer-BioNTech vaccines at 28
and 84 day intervals. Published results of the 28 day interval comparison
demonstrated a more robust immune response for the
AstraZeneca/COVISHIELD COVID-19 vaccine followed by the Pfizer-
BioNTech vaccine one month following the second dose, compared to a
homologous schedule with the AstraZeneca/COVISHIELD COVID-19 vaccine
(Liu et al., 2021). Data on immunogenicity for the 84 day schedule is
forthcoming. For more information, see the study website: https://comcovstudy.org.uk/home
• Emerging evidence indicates that heterologous COVID-19 schedules have an
acceptable safety profile. There is direct evidence on the safety of heterologous
COVID-19 immunization schedules (AstraZeneca and Pfizer-BioNTech) from
three studies at dosing intervals between 4 and 12 weeks.
• There is a possibility of increased short-term side effects when using
heterologous COVID-19 vaccine schedules, including headache, fatigue and
myalgia. These side effects are relatively mild, temporary and resolved without
complications.

Spoiler: show

Rare cases of a specific syndrome that involves serious blood clots (at
unusual sites such as cerebral venous sinus) associated with
thrombocytopenia have been reported after vaccination with viral vector
vaccines. Investigations to better understand this syndrome, often referred to
as Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT), are
ongoing. These events often occur between 4 and 28 days after receipt of the
vaccine.
 Early identification and appropriate treatment are critical.
 Clots related to VITT can be very aggressive and can be challenging
to treat with potential associated long-term morbidity. Ontario’s
Science Advisory Table has provided treatment and diagnosis
guidance for Emergency Department and Inpatient settings and Outpatient settings.
 The case fatality rate of VITT also varies between countries, and
ranges between 20 and 50% (NACI).
• Currently, the reported risk of VITT after the second dose of AstraZeneca /
COVISHIELD COVID-19 vaccine is lower than after the first dose. With increased
observation times, VITT rates have generally increased, including the risk
estimate following the second dose. Risk estimates are continually updated as
new data become available.
o The rate of VITT is estimated to be between 1 per 26,000 and 1 per 100,000
persons vaccinated with a first dose of an AstraZeneca/COVISHIELD COVID-
19 vaccine (NACI). The rate of VITT in Canada after a first dose has been
estimated to be approximately 1 per 55,000 doses administered (Ontario
Science Advisory Table).
o At this time, data from the United Kingdom (UK) suggests that the rate of VITT
following the second dose is approximately 1 per 600,000 doses
administered (31 events following 19.6 million second doses administered in
the UK as of June 16, 2021). Information from the UK is regularly reviewed
and reported because many millions of second doses of AstraZeneca COVID-
19 vaccine have been administered in this country. This report is updated
weekly and can be found here: Coronavirus vaccine - weekly summary of
Yellow Card reporting - GOV.UK (www.gov.uk).

it seems to work but there's also a dozen potential complications if you mix az with anything that don't seem to pop up if you mix pfizer/moderna

[Zealot]

CDC is going to restore masking indoors guidance even for the vaccinated in states where the virus is surging again.

Sent from my SM-N981U using Tapatalk

[Tyrath]

Good luck getting people to comply D:

[kuronosan]

I think it's about as equal to the rate of vaccination at this point. People who are going to comply are likely already taking these measures in public. Those that are on the fence or "over it" aren't going to mask up no matter what. From here on out we're in the Darwin period and will probably see surges before we see compliance. As for increased deaths that's difficult to say.

[archibaldcrane]

They'll mask if it's required (like here) but otherwise no

[Day]

Thats what I do

[Tymon]

https://twitter.com/Yamiche/status/1420027166843097092

May only fall on a small section of the population, of course this means nothing as it's up to businesses and governments to require anything

[synistar]

Following suit with University of California, the California State University system is also going to require all staff, faculty, and students to be vaccinated with exceptions based on religious or medical reasons. However, CSU will not exclude students from student activities and facilities like the UC system would. CSU will require unvaccinated individuals to be tested regularly.

CSU will not require proof of vaccination instead relying an attestation. Individual campuses may independently request proof of vaccination.

I expect a shitshows in the rural campuses of Chico and Humboldt. Probably at SDSU, too.

[Tymon]

https://twitter.com/yabutaleb7/statu...50096079712262

If this is true I think a lot of places are going to have to rethink what their goal is now

If zero or near zero community spread is the goal then we need strict restrictions/lockdowns for the long haul. If a vaccinated person can still spread like anybody else then there is no end possible without total isolation

If not then mandate vaccines or just call it game set match and let the unvaxxed deal with the consequences. Which won't happen cuz of kids. Catch 22, impossible situation imo

[Rhyis.]

this is why i think masks will be around for a long ass time, at least up here. it's impossible to get an entire population vaccinated. how do you account for the homeless, those too young to receive the vaccine, etc? there will always be people that are still susceptible to covid killing them

[archibaldcrane]

https://twitter.com/ddiamond/status/...631582209?s=19

[Tymon]

this is why i think masks will be around for a long ass time, at least up here. it's impossible to get an entire population vaccinated. how do you account for the homeless, those too young to receive the vaccine, etc? there will always be people that are still susceptible to covid killing them

Lot of people will check you at the door on that logic, given that first world countries broadly have totally ignored these people despite numerous other diseases that routinely debilitate their populations (speaking of homeless here)